產品屬性：
產品名稱 | Lacosamide |
規格 | 5 mg、10 mg、25 mg、50 mg |
貨號 | EY-01Y16623 |
Cas No.: 175481-36-4
別名: N/A
化學名: N/A
分子式: C13H18N2O3
分子量: 250.3
溶解度: DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 20 mg/ml,PBS (pH 7.2): 2 mg/ml
儲存條件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產品描述：
Lacosamide selectively enhances sodium channel slow inactivation without affecting fast inactivation.1 It is effective in multiple rodent models of seizure activity.2 The neuroprotective effects of lacosamide are also attributed to its ability to modulate collapsin response mediator protein 2 (CRMP-2), a member of the semaphorin signal transduction pathway.1,3 Formulations containing lacosamide have been used as an adjunctive or monotherapy for focal-onset seizures but, at higher doses, have a low potential for abuse.4 Lacosamide is regulated as a Schedule V compound in the United States.1.Sheets, P.L., Heers, C., Stoehr, T., et al.Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepineJ. Pharmacol. Exp. Ther.326(1)89-99(2008)
2.Luszczki, J.J.Third-generation antiepileptic drugs: Mechanisms of action, pharmacokinetics and interactionsPharmacol. Rep.61(2)197-216(2009)
3.Doty, P., Rudd, G.D., Stoehr, T., et al.LacosamideNeurotherapeutics4(1)145-148(2007)
4.Strzelczyk, A., Zollner, J.P., Willems, L.M., et al.Lacosamide in status epilepticus: Systematic review of current evidenceEpilepsia58(6)933-950(2017)
特別提醒公司產品僅供科研使用
